Viridian legal chief amends tax share disposition

Viridian Therapeutics Chief Legal Officer updates prior tax-related share filing.

Accepted by SEC EDGAR 03/09/2026 - 07:35 PM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

4/A

Rhea-AI Filing Summary

Viridian Therapeutics Chief Legal Officer updates prior tax-related share filing. Jennifer Tousignant filed an amended Form 4 to correct the number of shares and price previously reported as disposed to cover taxes. The amendment now shows a tax-withholding disposition of 1,675 shares of common stock at $30.19 per share on March 3, 2026, leaving her with 3,494 shares of Viridian Therapeutics common stock held directly.

Insider Trade Summary

Exercise Price or Tax Liability: 1,675 shares

Exercise Price or Tax Liability 1 txn

Insider Tousignant Jennifer

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	1,675	$30.19	$51K

Holdings After Transaction: Common Stock — 3,494 shares (Direct)

Holdings Before and After: Common Stock, 5,169 to 3,494 shares (Direct)

Footnotes (1)

F1. This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Viridian Therapeutics (VRDN) disclose in this amended Form 4?

Viridian Therapeutics reported that Chief Legal Officer Jennifer Tousignant filed an amended Form 4. It corrects the number of shares and price previously reported as disposed to cover taxes and updates her total directly owned common shares after the tax-withholding transaction.

How many Viridian Therapeutics (VRDN) shares were disposed for taxes?

The amended filing shows a tax-withholding disposition of 1,675 shares of Viridian Therapeutics common stock. These shares were delivered to cover tax obligations, rather than as an open-market sale, according to the Form 4 transaction code and description.

At what price were the Viridian Therapeutics (VRDN) shares used for tax withholding valued?

The 1,675 shares disposed to cover taxes were valued at $30.19 per share. This price is used in the Form 4 to report the tax-withholding transaction, which is classified as a payment of tax liability by delivering securities.

How many Viridian Therapeutics (VRDN) shares does Jennifer Tousignant own after this amendment?

After correcting the prior Form 4, the amended filing shows Jennifer Tousignant directly beneficially owns 3,494 shares of Viridian Therapeutics common stock. This total reflects all transactions reported in the initial Form 4 and the revised tax-withholding amounts.

Why was an amended Form 4 filed for Viridian Therapeutics (VRDN)?

The amended Form 4 was filed to correct the previously reported number of shares and price used to cover taxes, as well as the resulting total beneficial ownership. The footnote explains the amendment updates all figures from the initial Form 4 filed on March 4, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tousignant Jennifer

(Last)

(First)

(Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM

02453

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
03/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/03/2026		F		1,675⁽¹⁾	D	$30.19	3,494⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4.

	/s/Jennifer Tousignant	03/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR